Comparable efficacy-safety and better renal function with everolimus and reduced-exposure tacrolimus versus standard-exposure tacrolimus in liver transplant recipients: H2304 and H2307 pooled analysis

被引：0
|
作者：
Levy, G. [1 ]
Lee, S. G. [2 ]
Jeng, L. -B [3 ]
Soin, A. S. [4 ]
Lee, W. -C [5 ]
De Simone, P. [6 ]
Nevens, F. [7 ]
Suh, K. -S [8 ]
Fischer, L. [9 ]
Joo, D. J. [10 ]
Fung, J. [11 ]
Joh, J. -W [12 ]
Kaido, T. [13 ]
Grant, D. [14 ]
Meier, M. [15 ]
Sips, C. [15 ]
Kaneko, S. [16 ]
Saliba, F. [17 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Asan Med Ctr, Seoul, South Korea
[3] China Med Univ Hosp, Taichung, Taiwan
[4] Medic Hosp, Medanta, Gurgaon, India
[5] Chang Gung Mem Hosp, Taoyuan, Taiwan
[6] Azienda Osped Univ Pisana, Pisa, Italy
[7] Univ Hosp Gasthuisberg, Leuven, Belgium
[8] Seoul Natl Univ, Coll Med, Seoul, South Korea
[9] Univ Med Ctr Eppendorf, Hamburg, Germany
[10] Yonsei Univ, Coll Med, Seoul, South Korea
[11] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[12] Samsung Med Ctr, Seoul, South Korea
[13] Kyoto Univ Hosp, Kyoto, Japan
[14] Toronto Gen Hosp, Toronto, ON, Canada
[15] Novartis Pharma AG, Basel, Switzerland
[16] Novartis Pharma KK, Tokyo, Japan
[17] Hop Paul Brousse, Villejuif, France
来源：
TRANSPLANTATION | 2019年 / 103卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
O-059
引用
收藏
页码：36 / 36
页数：1
相关论文
共 47 条
  • [1] Renal Function and HCC Recurrence As Well As Safety of Everolimus with Reduced Tacrolimus Versus Standard Tacrolimus in Deceased and Living Donor Liver Transplant Recipients: Pooled Analysis of H2304 and H2307 Studies
    Lee, Sung Gyu
    Jeng, Long Bin
    Saliba, Faouzi
    Soin, Arvinder Singh
    Lee, Wei-Chen
    De Simone, Paolo
    Nevens, Frederik
    Suh, Kyung-Suk
    Fischer, Lutz
    Joo, DongJin
    Fung, John J.
    Joh, Jae-Won
    Kaido, Toshimi
    Grant, David R.
    Meier, Matthias
    Barbara, Rauer
    Sips, Carole
    Kaneko, Shuhei
    Levy, Gary A.
    HEPATOLOGY, 2018, 68 : 6A - 6A
  • [2] EVALUATING THE EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED TACROLIMUS VERSUS STANDARD TACROLIMUS IN LIVING DONOR LIVER TRANSPLANT RECIPIENTS: H2307 STUDY DESIGN
    Sips, C.
    Suh, K. S.
    Joh, J. W.
    Yoshizumi, T.
    Lee, W. C.
    Genyk, Y.
    Martzloff, E. -D.
    Wang, Z.
    Lopez, P.
    Grant, D.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S858 - S859
  • [3] Effects of Everolimus and Tacrolimus Exposure on Efficacy and Renal Function in Liver Transplant Recipients at 24 Months in a Randomized Trial (H2304)
    Fischer, L.
    Kaiser, G.
    Koneru, B.
    Toselli, L.
    Durand, F.
    Heaton, N.
    Shetty, K.
    Dong, G.
    Lopez, P.
    Junge, G.
    Kovarik, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 117 - 118
  • [4] Baseline Characteristics from Recipients of Living and Deceased Donors in Liver Transplantation Receiving Everolimus Plus Reduced Tacrolimus or Standard Tacrolimus, with Steroids: Data from H2307 and H2304 Studies
    Jeng, L. B.
    Levy, G.
    Suh, K. S.
    Joo, D. J.
    Lee, W. C.
    Chen, C. L.
    Soin, A. S.
    Joh, J. W.
    Yoshizumi, T.
    Grant, D.
    Saliba, F.
    Sips, C.
    Dong, G.
    Lopez, P.
    Aguilar, J.
    Lee, S. G.
    TRANSPLANTATION, 2016, 100 : S227 - S227
  • [5] EVEROLIMUS WITH REDUCED TACROLIMUS VERSUS STANDARD TACROLIMUS IN LIVING-DONOR LIVER TRANSPLANT RECIPIENTS: BASELINE DATA FROM THE H2307 STUDY
    Lopez, Patricia
    Levy, Gary
    Jeng, Long-Bin
    Suh, Kyung Suk
    Joo, Dong Jin
    Lee, Sung Gyu
    Lee, Wei-Chen
    Chen, Chao-Long
    Soin, Arvinder Singh
    Joh, Jae Won
    Yoshizumi, Tomoharu
    Grant, David
    Martzloff, El-Djouher
    Sips, Carole
    Wang, Zailong
    TRANSPLANT INTERNATIONAL, 2015, 28 : 459 - 459
  • [6] EVEROLIMUS WITH REDUCED TACROLIMUS VERSUS STANDARD TACROLIMUS IN LIVING-DONOR LIVER TRANSPLANT RECIPIENTS: BASELINE DATA FROM THE H2307 STUDY
    Settmacher, U.
    Braun, F.
    Sips, C.
    Dong, G.
    Kroeger, I.
    Sanchez, J. Aguilar
    TRANSPLANT INTERNATIONAL, 2015, 28 : 32 - 32
  • [7] Renal Function with Everolimus and Reduced Tacrolimus in De Novo Liver Transplant Recipients: 12 Month Results of the H2304 Study
    De Simone, P.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fischer, L.
    Foltys, D.
    Koneru, B.
    Wang, Y.
    Hexham, J. M.
    Junge, G.
    Fung, J.
    LIVER TRANSPLANTATION, 2012, 18 : S85 - S86
  • [8] Efficacy and Safety of Everolimus With Reduced Tacrolimus in Living-Donor Liver Transplant Recipients: Baseline Data from the H2307 Study
    Levy, G.
    Suh, K. S.
    Joh, J. W.
    Yoshizumi, T.
    Lee, W. C.
    Genyk, Y.
    Grant, D.
    Martzloff, E. -D.
    Sips, C.
    Wang, Z.
    Lopez, P.
    TRANSPLANTATION, 2015, 99 : 150 - 150
  • [9] Efficacy and Safety of Everolimus with Reduced Tacrolimus in Living-Donor Liver Transplant (LDLT) Recipients with Hepatocellular Carcinoma: Subgroup Analysis from the H2307 Study
    Jeng, L. -B.
    Lee, S. -G.
    Lee, W. -C.
    Suh, K. -S.
    Joo, D. J.
    Joh, J.
    Kaido, T.
    Lopez, P.
    Kochuparampil, J.
    Kaneko, S.
    Levy, G.
    TRANSPLANTATION, 2017, 101 (05) : 375 - 376
  • [10] The H2304E1 Study: Efficacy and Safety of Everolimus With Reduced Tacrolimus Versus Standard Tacrolimus in De Novo Liver Transplant Recipients at 36 Months.
    De Simone, P.
    Kaiser, G. M.
    De Carlis, L.
    Metselaar, H. J.
    Duvoux, C.
    Nevens, F.
    Fischer, L.
    Fung, J.
    Dong, G.
    Rauer, B.
    Junge, G.
    Saliba, F.
    LIVER TRANSPLANTATION, 2014, 20 : S106 - S106
12345